| Obesity in adults: a clinical practice guideline S Wharton, DCW Lau, M Vallis, AM Sharma, L Biertho, ... Cmaj 192 (31), E875-E891, 2020 | 992 | 2020 |
| An overview of links between obesity and mental health C Avila, AC Holloway, MK Hahn, KM Morrison, M Restivo, R Anglin, ... Current obesity reports 4, 303-310, 2015 | 324 | 2015 |
| Treating negative symptoms in schizophrenia: an update G Remington, G Foussias, G Fervaha, O Agid, H Takeuchi, J Lee, M Hahn Current treatment options in psychiatry 3, 133-150, 2016 | 203 | 2016 |
| Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia NE MacKenzie, C Kowalchuk, SM Agarwal, KA Costa-Dookhan, ... Frontiers in psychiatry 9, 622, 2018 | 183 | 2018 |
| The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment AT Raben, VS Marshe, A Chintoh, I Gorbovskaya, DJ Müller, MK Hahn Frontiers in neuroscience 11, 741, 2018 | 110 | 2018 |
| Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis D Siskind, M Hahn, CU Correll, A Fink‐Jensen, AW Russell, N Bak, ... Diabetes, Obesity and Metabolism 21 (2), 293-302, 2019 | 99 | 2019 |
| The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain S Kanji, TM Fonseka, VS Marshe, V Sriretnakumar, MK Hahn, DJ Müller European archives of psychiatry and clinical neuroscience 268, 3-15, 2018 | 88 | 2018 |
| Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use G Remington, J Lee, O Agid, H Takeuchi, G Foussias, M Hahn, G Fervaha, ... Expert opinion on drug safety 15 (9), 1193-1203, 2016 | 84 | 2016 |
| Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls MK Hahn, TMS Wolever, T Arenovich, C Teo, A Giacca, V Powell, ... Journal of clinical psychopharmacology 33 (6), 740-746, 2013 | 81 | 2013 |
| Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model M Hahn, A Chintoh, A Giacca, L Xu, L Lam, S Mann, P Fletcher, ... Schizophrenia research 131 (1-3), 90-95, 2011 | 80 | 2011 |
| Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic–induced weight gain LK Ellinger, HJ Ipema, JM Stachnik Annals of Pharmacotherapy 44 (4), 668-679, 2010 | 80 | 2010 |
| Clozapine’s role in the treatment of first-episode schizophrenia G Remington, O Agid, G Foussias, M Hahn, N Rao, M Sinyor American Journal of Psychiatry 170 (2), 146-151, 2013 | 77 | 2013 |
| Membrane topology and sequence requirements for oil body targeting of oleosin BM Abell, M Hahn, LA Holbrook, MM Moloney The Plant Journal 37 (4), 461-470, 2004 | 77 | 2004 |
| Direct and indirect control of hepatic glucose production by insulin GF Lewis, AC Carpentier, S Pereira, M Hahn, A Giacca Cell metabolism 33 (4), 709-720, 2021 | 76 | 2021 |
| Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans F Caravaggio, C Borlido, M Hahn, Z Feng, G Fervaha, P Gerretsen, ... International Journal of Neuropsychopharmacology 18 (7), pyv014, 2015 | 76 | 2015 |
| The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review P Shah, Y Iwata, E Plitman, EE Brown, F Caravaggio, J Kim, S Nakajima, ... Psychiatry research 268, 114-122, 2018 | 75 | 2018 |
| Antipsychotics and glucose metabolism: how brain and body collide C Kowalchuk, LN Castellani, A Chintoh, G Remington, A Giacca, ... American Journal of Physiology-Endocrinology and Metabolism 316 (1), E1-E15, 2019 | 74 | 2019 |
| Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies OC Melamed, MK Hahn, SM Agarwal, VH Taylor, BH Mulsant, P Selby General Hospital Psychiatry 66, 30-33, 2020 | 68 | 2020 |
| Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients AK Tiwari, EJ Brandl, C Weber, O Likhodi, CC Zai, MK Hahn, ... Journal of clinical psychopharmacology 33 (1), 11-17, 2013 | 68 | 2013 |
| Atypical antipsychotics and diabetic ketoacidosis: a review MD Guenette, M Hahn, TA Cohn, C Teo, GJ Remington Psychopharmacology 226, 1-12, 2013 | 67 | 2013 |
Araba ChintohUniversity of Toronto; Centre for Addiction and Mental HealthVerified email at utoronto.ca
